Leptomeningeal Metastases (LM)
CNSYCerenome, Inc.Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for REYOBIQ (Rhenium Re186 Obisbemeda) in Leptomeningeal Metastases (LM). The expected timing is based on the latest available company guidance and may change.
05/15/26:- SpectronRx added. ReSPECT-LM Ph2 dose optimization continues. Data expected Q3 2026. 07/28/26:- ReSPECT-LMM repeated-dosing emerging data in LM to be presented Aug 13, 2026. 08/14/26:- ReSPECT-LM multiple-dose enrollment reached about one-third. Ph2 data is expected Q3 2026; optimal dosing will be defined by year-end.
Verification
Confirm timing and program details against the company announcement or filing.